Hantech Bio-Technology Co., Ltd.

Total Valuation

Hantech Bio-Technology Co., Ltd. carries a market capitalization of 1.77B, placing it among publicly traded companies globally. Its enterprise value stands at 1.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Hantech Bio-Technology Co., Ltd. currently has 30.27M shares outstanding.

Valuation Ratios

Hantech Bio-Technology Co., Ltd. trades at a trailing price-to-earnings ratio of 14.87. The price-to-sales ratio is 2.66, and the price-to-book ratio stands at 4.14.

Enterprise Valuation

On an enterprise value basis, Hantech Bio-Technology Co., Ltd. trades at an EV/EBITDA multiple of 10.49 and an EV/FCF ratio of 10.19. The EV/Sales ratio of 2.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.49 provides insight into valuation relative to core operating earnings.

Financial Position

Hantech Bio-Technology Co., Ltd. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.68, indicating elevated leverage, while an interest coverage ratio of 58.30 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Hantech Bio-Technology Co., Ltd. posts a return on equity of 28.04 and a return on invested capital of 14.78.

Taxes

Over the trailing twelve months, Hantech Bio-Technology Co., Ltd. has paid 33.93M in income taxes, reflecting an effective tax rate of 19.61.

Stock Price Statistics

Hantech Bio-Technology Co., Ltd.'s stock has gained approximately 7.59027% over the past 52 weeks. The 50-day moving average sits at 65.25, while the 200-day moving average is 65.62.

Income Statement

Over the trailing twelve months, Hantech Bio-Technology Co., Ltd. generated 778.54M in revenue and converted that into 139.05M in net income, yielding earnings per share of 4.35. EBITDA reached 173.55M, while operating income came in at 173.55M.

Balance Sheet

Hantech Bio-Technology Co., Ltd. holds 339.38M in cash and equivalents against 88.90M in total debt, resulting in a net debt position of -180.10M. Total book value stands at 499.24M, with working capital of 345.06M providing operational flexibility.

Cash Flow

Hantech Bio-Technology Co., Ltd. produced 160.63M in operating cash flow over the past twelve months. After subtracting -15.62M in capital expenditures, free cash flow totaled 145.01M - equivalent to 4.61 per share.

Margins

Hantech Bio-Technology Co., Ltd. operates with a gross margin of 37.11, reflecting its pricing power and cost economics. The operating margin of 22.29 and net profit margin of 17.86 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Hantech Bio-Technology Co., Ltd.'s most recent stock split took place on July 3, 2026 with a 5:6 split ratio.

Scores

Hantech Bio-Technology Co., Ltd. posts an Altman Z-Score of 5.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.